Altre lingue Medicus Pharma Ltd.

Azioni

MDCX

CA58471K1030

Mercato chiuso - Toronto S.E. Altri mercati azionari 21:57:42 09/07/2024			Variaz. 5gg	Var. 1 gen.
2,48 ^CAD	+7,83%		+45,03%	+24,00%

05/07	Medicus Pharma sale del 7,4% grazie alla chiusura del collocamento privato e alla conversione delle note convertibili	MT
21/03	Medicus Pharma Ltd. annuncia il ricevimento di commenti da parte della Food and Drug Administration statunitense	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Medicus Pharma Ltd. announced that it has received $11.0175 million in funding	08/07
Medicus Pharma up 7.4% as it Closes Private Placement, Conversion of Convertible Notes	05/07
Medicus Pharma Ltd. Announces Closing of Non-Brokered Private Placement of Common Shares and Conversion of Convertible Notes	05/07
Medicus Pharma Ltd. announced that it has received $5.845 million in funding	05/07
Medicus Pharma Ltd. Announces Proposed Non-Brokered Private Placement of Common Shares and Conversion of Convertible Notes	27/06
Medicus Pharma Ltd. announced that it expects to receive $5.845 million in funding	26/06
Medicus Pharma Files Registration Statement for Proposed Initial Public Offering in the United States	29/05
Medicus Pharma Ltd. Announces Filing of Registration Statement for Proposed Initial Public Offering in the United States	29/05
Medicus Pharma Plans Private Placement for Clinical Development Acceleration	07/05
Medicus Pharma Ltd. Announces Closing of Private Placement of Convertible Notes	04/05
Medicus Pharma Ltd. announced that it expects to receive $11.0175 million in funding	03/05
Canadian Investment Regulatory Organization Trade Resumption - MDCX	25/04
Medicus Pharma Ltd. Announces Proposed Private Placement of Convertible Notes	25/04
Canadian Investment Regulatory Organization Trading Halt - MDCX	25/04
Medicus Pharma Ltd. announced a financing transaction	25/04
Medicus Pharma says U.S. FDA has provided comments on Phase 2 Clinical Protocol of SKNJCT-003	28/03
Medicus Pharma Ltd. Announces the Receipt of Comments from the U.S Food and Drug Administration	21/03
Medicus Pharma Ltd. Receives FDA Comments on Phase 2 Clinical Protocol to Non-Invasively Treat Basal Cell Carcinoma of the Skin	21/03
Medicus Pharma Names COO	05/03
Medicus Pharma Ltd. Announces Appointment of Erica Monaco as Chief Operating Officer	05/03

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Medicus Pharma Ltd.

Azioni

MDCX

CA58471K1030

Altre lingue

Filtri